Completion of treatment · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: baclofen versus clonidine compared with other pharmacological detoxification treatment (very low certainty).
4 findings from 1 review
RR 1.06 [0.63, 1.8]
66 participants
Very low
RR 2.01 [1.69, 2.38]
361 participants
Low
RR 0.95 [0.65, 1.37]
72 participants
Very low
Show 1 more finding
Withdrawal symptoms · management of opium withdrawal
4 findings from 1 review
Show 1 more finding
no estimate extracted
34 participants
Very low
Completion of treatment: clonidine versus clonidine plus amantadine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus clonidine plus amantadine,… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.03 [0.86, 1.24]
69 participants
Very low
Completion of treatment: clonidine versus buprenorphine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus buprenorphine, inpatient… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.04 [0.9, 1.2]
35 participants
Very low
Completion of treatment: methadone versus methadone plus gabapentin · management of opium withdrawal
Pharmacological detoxification treatment showed no clear difference in completion of treatment: methadone versus methadone plus gabapentin compared with other pharmacological detoxification treatment (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
1 finding from 1 review
Death (all causes) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in adverse events (grade ≥ 3) compared with standard therapies (low certainty).
1 finding from 1 review
QoL · previously untreated patients with mRCC
5 findings from 1 review
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
Show 2 more findings
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
1 finding from 1 review
Short‐term improvement as measured on a continuous scale ( · adults with panic disorder
1 finding from 1 review
Short‐term remission · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term remission ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Short‐term response ( · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term response ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Short‐term dropouts ( · adults with panic disorder
It is very uncertain whether cognitive behaviour therapy changes short‐term dropouts ( compared with psychodynamic psychotherapy (very low certainty).
1 finding from 1 review
Long‐term remission/response · adults with panic disorder
Cognitive behaviour therapy showed no clear difference in long‐term remission/response ( compared with psychodynamic psychotherapy (low certainty).
1 finding from 1 review
Short‐term improvement as measured on a continuous scale ( · adults with panic disorder
1 finding from 1 review